Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 5/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.64 |
| ▸ | MKNK2 | Q9HBH9 | 5/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.64 |
| ▸ | AXL | P30530 | 1/20 | 0.64 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.57 |
| ▸ | KIF11 | P52732 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29818169 | 1.00 | CYP2A6 (0.68) | CYP2A6CYP3A4ALDH1A1CYP1A2MKNK1 | |
| SCHEMBL18745788 | 1.00 | CYP2A6 (0.68) | CYP2A6CYP3A4ALDH1A1CYP1A2MKNK1 | |
| SCHEMBL18745701 | 0.92 | MKNK1 (0.72) | CYP2A6CYP3A4ALDH1A1CYP1A2MKNK1 | |
| SCHEMBL18745798 | 0.92 | MKNK1 (0.63) | CYP2A6CYP3A4ALDH1A1CYP1A2MKNK1 | |
| SCHEMBL11170593 | 0.89 | AXL (0.86) | CYP2A6CYP3A4ALDH1A1CYP1A2MKNK1 | |
| SCHEMBL28191166 | 0.89 | CYP2A6 (0.54) | CYP2A6CYP3A4ALDH1A1CYP1A2MKNK1 | |
| SCHEMBL24534338 | 0.88 | CYP2A6 (0.88) | CYP2A6CYP3A4ALDH1A1CYP1A2MKNK1 | |
| SCHEMBL29360677 | 0.88 | CYP2A6 (0.88) | CYP2A6CYP3A4ALDH1A1CYP1A2MKNK1 | |
| SCHEMBL13907273 | 0.88 | CYP2A6 (0.88) | CYP2A6CYP3A4ALDH1A1CYP1A2MKNK1 | |
| SCHEMBL18745763 | 0.87 | CYP2A6 (0.57) | CYP2A6CYP3A4ALDH1A1CYP1A2MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 331 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109134351-B | Synthesis method of S-3- (4-aminophenyl) piperidine | 武汉理工大学 | 2022-03-11 | — | — | CN | claimed |
| US-20210145818-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | Poviva Corp. | 2021-05-20 | — | — | US | claimed |
| EP-3781163-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | Poviva Corp. (US) | 2021-02-24 | — | — | EP | claimed |
| EP-3284467-B1 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITIONS | NICONOVUM USA INC (US) | 2019-10-30 | — | — | EP | claimed |
| WO-2019202396-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | POVIVA TEA, LLC (US) | 2019-10-24 | — | — | WO | claimed |
| CN-109134351-A | S-3-(4- aminophenyl) piperidines synthetic method | 武汉理工大学 | 2019-01-04 | — | — | CN | claimed |
| US-9937168-B2 | Nicotine-containing pharmaceutical compositions | NICONOVUM USA, INC. (US) | 2018-04-10 | — | — | US | claimed |
| EP-3284467-A1 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITIONS | Niconovum USA, Inc. (US) | 2018-02-21 | — | — | EP | claimed |
| EP-2566476-B1 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITIONS | NICONOVUM USA INC (US) | 2017-11-22 | — | — | EP | claimed |
| EP-2050749-B1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-11-22 | — | — | EP | claimed |
| CN-102892418-A | Nicotine-containing pharmaceutical compositions | NICONOVUM USA INC | 2013-01-23 | — | — | CN | claimed |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-18 | — | — | US | claimed |
| WO-2009125923-A2 | NOVEL INDOL CARBOXYLIC ACID BISPYRIDYL CARBOXAMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD AND COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESERACH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2009-10-15 | — | — | WO | claimed |
| US-20090258876-A1 | NOVEL INDOL CARBOXYLIC ACID BISPYRIDYL CARBOXAMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD AND COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2009-10-15 | — | — | US | claimed |
| EP-2108649-A1 | Novel indol carboxylic acid bispyridyl carboxamide derivatives as 5-HT2c receptor antagonists | Korea Research Institute of Chemical Technology (KR) | 2009-10-14 | — | — | EP | claimed |
| EP-2050749-A1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-22 | — | — | EP | claimed |
| US-20080207694-A1 | Hydroxamates as Histone Deacetylase Inhibitors and Pharmaceutical Formulations Containing Them | ROSSI CRISTINA | 2008-08-28 | — | — | US | claimed |
| EP-1868997-A1 | HYDROXAMATES AS HISTONE DEACETYLASE INHIBITORS AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM | Menarini International Operations Luxembourg S.A. (LU) | 2007-12-26 | — | — | EP | claimed |
| WO-2006097460-A1 | HYDROXAMATES AS HISTONE DEACETYLASE INHIBITORS AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM | MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. (LU) | 2006-09-21 | — | — | WO | claimed |
| EP-0740930-A1 | BLOOD FLOW IMPROVER AND COSMETIC | POLA CHEMICAL INDUSTRIES, INC. (JP) | 1996-11-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | PIK3CA, AKT3, AKT1 | CYP2A6 3158/4885CYP3A4 3027/4885ALDH1A1 2102/4885 |
| US-20210145818-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | CHRNA5, SLC18A3, CHRNA6 | CYP2A6 1222/4885CYP3A4 1962/4885ALDH1A1 2986/4885 |
| US-20080207694-A1 | Hydroxamates as Histone Deacetylase Inhibitors and Pharmaceutical Formulations Containing Them | HDAC1, HDAC8, HDAC9 | CYP2A6 2796/4885CYP3A4 2599/4885ALDH1A1 1106/4885 |
| US-20090258876-A1 | NOVEL INDOL CARBOXYLIC ACID BISPYRIDYL CARBOXAMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD AND COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT | HTR2C, HTR5A, HTR2A | CYP2A6 1322/4885CYP3A4 806/4885ALDH1A1 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.